Literature DB >> 16117735

Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model.

Jens Kristensen1, Michael Maeng, Michael Rehling, Jette S Berg, Ulrik M Mortensen, Søren S Nielsen, Torsten T Nielsen.   

Abstract

BACKGROUND: Recombinant human erythropoietin (rhEPO) has been proposed to possess important tissue protective, apart from haematopoietic, effects. Cardioprotective effects have thus been reported in rodents exposed to myocardial ischaemia. Pathways common to the mediation of ischaemic preconditioning may be involved. Before clinical testing such possible cardioprotective effects needs assessment in an experimental large animal model with closer similarity to human ischaemic pathophysiology.
METHODS: A control group and two rhEPO groups were studied. EPO1 pigs were given EPO corresponding to the early window and EPO2 pigs to the early and late window of ischaemic preconditioning in a closed chest, catheter-based, porcine coronary occlusion model (45 min of occlusion of the left anterior descending artery). Infarct size as a proportion of the ischaemic area (IS/AAR) was measured in vivo by myocardial perfusion imaging (MPI) and postmortem by a histochemical procedure (at 150 min of reperfusion).
RESULTS: IS/AAR did not differ significantly between control (C), EPO1 and EPO2 groups, neither measured by MPI (mean+/-SD for C: 0.87+/-0.13; EPO1: 0.92+/-0.08; EPO2: 0.87+/-0.11), nor histochemically (mean+/-SD for C: 0.64+/-0.20; EPO1: 0.75+/-0.17; EPO2: 0.80+/-0.07). In the EPO2 group mean arterial pulmonary pressure and dP/dtmax were increased compared with control group.
CONCLUSION: Despite promising results from studies in rodents, rhEPO did not reduce infarct size measured after 2.5 h of reperfusion in our porcine model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117735     DOI: 10.1111/j.1475-097X.2005.00626.x

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  7 in total

1.  Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.

Authors:  Samer S Najjar; Sunil V Rao; Chiara Melloni; Subha V Raman; Thomas J Povsic; Laura Melton; Gregory W Barsness; Kristi Prather; John F Heitner; Rakhi Kilaru; Luis Gruberg; Vic Hasselblad; Adam B Greenbaum; Manesh Patel; Raymond J Kim; Mark Talan; Luigi Ferrucci; Dan L Longo; Edward G Lakatta; Robert A Harrington
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

2.  Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats.

Authors:  X Liu; Z Zhou; X Feng; Z Jia; Y Jin; J Xu
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

3.  Myocardial infarction: cardioprotection by erythropoietin.

Authors:  Mark I Talan; Roberto Latini
Journal:  Methods Mol Biol       Date:  2013

Review 4.  Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?

Authors:  Roberto Latini; Michael Brines; Fabio Fiordaliso
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

5.  Erythropoietin in the critically ill: do we ask the right questions?

Authors:  Oscar McCook; Michael Georgieff; Angelika Scheuerle; Peter Möller; Christoph Thiemermann; Peter Radermacher
Journal:  Crit Care       Date:  2012-09-26       Impact factor: 9.097

6.  Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium.

Authors:  Emil Ruvinov; Orna Sharabani-Yosef; Arnon Nagler; Tom Einbinder; Micha S Feinberg; Radka Holbova; Amos Douvdevani; Jonathan Leor
Journal:  Fibrogenesis Tissue Repair       Date:  2008-11-03

7.  An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium.

Authors:  Soroush Seifirad
Journal:  Front Physiol       Date:  2014-02-11       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.